Published in J Natl Cancer Inst on December 28, 2011
Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell (2015) 2.01
Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y? Cell Death Differ (2013) 1.01
Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer (2013) 0.94
YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment. Oncotarget (2015) 0.90
p53-directed translational control can shape and expand the universe of p53 target genes. Cell Death Differ (2014) 0.89
YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells (2014) 0.89
Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. PLoS One (2013) 0.89
Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence. BMC Genomics (2013) 0.85
Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85
Cross-tissue Analysis of Gene and Protein Expression in Normal and Cancer Tissues. Sci Rep (2016) 0.83
The Many Virtues of tRNA-derived Stress-induced RNAs (tiRNAs): Discovering Novel Mechanisms of Stress Response and Effect on Human Health. J Biol Chem (2015) 0.81
Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer. PLoS One (2013) 0.79
Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis (2016) 0.76
Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations. Oncotarget (2016) 0.75
shRNA-Mediated Silencing of Y-Box Binding Protein-1 (YB-1) Suppresses Growth of Neuroblastoma Cell SH-SY5Y In Vitro and In Vivo. PLoS One (2015) 0.75
Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells. Mol Med Rep (2016) 0.75
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death Differ (2016) 0.75
Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target. J Cancer (2017) 0.75
Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis. Oncotarget (2017) 0.75
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. Exp Ther Med (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res (1998) 14.63
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
AmiGO: online access to ontology and annotation data. Bioinformatics (2008) 10.77
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev (2000) 6.07
Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev (1994) 4.93
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci U S A (1988) 3.64
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell (2009) 3.18
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res (2009) 3.08
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Mining for regulatory programs in the cancer transcriptome. Nat Genet (2005) 2.88
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci U S A (1998) 2.40
Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene (1988) 2.20
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol (1998) 2.10
Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol (1997) 2.00
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res (2008) 1.88
Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res (2007) 1.80
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2. Oncogene (2001) 1.48
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res (2006) 1.47
Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs. Mol Cell Biol (2007) 1.44
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem (1997) 1.39
Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene (1999) 1.39
Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer (1999) 1.37
YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res (2005) 1.37
Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res (2001) 1.33
Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res (1996) 1.33
Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem (2007) 1.32
Master regulators used as breast cancer metastasis classifier. Pac Symp Biocomput (2009) 1.32
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1. EMBO J (2001) 1.22
Twist promotes tumor cell growth through YB-1 expression. Cancer Res (2008) 1.22
A role for Y-box proteins in cell proliferation. Bioessays (1995) 1.18
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood (2007) 1.17
Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene (2000) 1.17
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene (2009) 1.16
Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem (2001) 1.12
The role of cellular transcription factor E2F in the regulation of cdc2 mRNA expression and cell cycle control of human hematopoietic cells. J Biol Chem (1994) 1.12
Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res (2007) 1.09
Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer (1999) 1.08
Y-box factor YB1 controls p53 apoptotic function. Oncogene (2005) 1.08
Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem (2004) 1.07
A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem (1993) 1.05
Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1. Oncogene (2010) 1.04
Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer (2010) 0.98
Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene (2005) 0.98
The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem (2003) 0.98
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing (2009) 0.92
Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene (2009) 0.91
A conserved stem loop motif in the 5'untranslated region regulates transforming growth factor-β(1) translation. PLoS One (2010) 0.90
Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol (2010) 0.87
Cloning and characterization of the human PAX2 promoter. J Biol Chem (1998) 0.82
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 2.92
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet (2005) 2.32
Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell (2004) 2.29
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
MicroRNA-regulated pathways associated with endometriosis. Mol Endocrinol (2008) 2.16
Microarray-based gene set analysis: a comparison of current methods. BMC Bioinformatics (2008) 2.06
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res (2007) 1.89
Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ (2011) 1.88
Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics (2005) 1.86
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages. Genesis (2002) 1.73
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology (2013) 1.63
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet (2013) 1.54
MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol (2013) 1.53
Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer. Clin Cancer Res (2004) 1.53
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update (2009) 1.49
Pseudomonas syringae pv. actinidiae from recent outbreaks of kiwifruit bacterial canker belong to different clones that originated in China. PLoS One (2013) 1.48
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Independent component analysis of microarray data in the study of endometrial cancer. Oncogene (2004) 1.48
Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem (2004) 1.46
Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res (2011) 1.45
YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J (2013) 1.38
Laboratory-acquired severe acute respiratory syndrome. N Engl J Med (2004) 1.37
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res (2002) 1.34
Positive regulation of c-Myc by cohesin is direct, and evolutionarily conserved. Dev Biol (2010) 1.34
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Heart Rhythm (2008) 1.33
Sensitivity of 70-mer oligonucleotides and cDNAs for microarray analysis of gene expression in Arabidopsis and its related species. Plant Biotechnol J (2004) 1.32
Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res (2009) 1.32
The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol (2006) 1.29
Transterm: a database to aid the analysis of regulatory sequences in mRNAs. Nucleic Acids Res (2008) 1.27
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
HIV induces maturation of monocyte-derived dendritic cells and Langerhans cells. J Immunol (2006) 1.24
The case for strategic international alliances to harness nutritional genomics for public and personal health. Br J Nutr (2005) 1.24
Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. J Infect Dis (2004) 1.24
The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res (2008) 1.23
Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol (2008) 1.22
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Transcriptomic analysis of the cardiac left ventricle in a rodent model of diabetic cardiomyopathy: molecular snapshot of a severe myocardial disease. Physiol Genomics (2006) 1.21
Genomic selection of reference genes for real-time PCR in human myocardium. BMC Med Genomics (2008) 1.19
Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. Nat Genet (2013) 1.18
Optimization and clinical validation of a pathogen detection microarray. Genome Biol (2007) 1.18
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
In the pursuit of complexity: systems medicine in cancer biology. Cancer Cell (2006) 1.15
Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther (2005) 1.15
Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res (2010) 1.14
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet (2013) 1.13
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res (2007) 1.11
Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res (2009) 1.10
Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest (2013) 1.09
A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res (2006) 1.09
Gene network inference and visualization tools for biologists: application to new human transcriptome datasets. Nucleic Acids Res (2011) 1.08
Y-box factor YB1 controls p53 apoptotic function. Oncogene (2005) 1.08
Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med (2006) 1.08
Identification of white spot syndrome virus latency-related genes in specific-pathogen-free shrimps by use of a microarray. J Virol (2003) 1.08
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res (2008) 1.07
The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J (2007) 1.07
Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol (2007) 1.07
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol (2003) 1.06
Diverse developmental disorders from the one ring: distinct molecular pathways underlie the cohesinopathies. Front Genet (2012) 1.06
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood (2011) 1.05
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. Fertil Steril (2006) 1.05
Microsatellite tandem repeats are abundant in human promoters and are associated with regulatory elements. PLoS One (2013) 1.04
A zebrafish model of Roberts syndrome reveals that Esco2 depletion interferes with development by disrupting the cell cycle. PLoS One (2011) 1.03
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells (2012) 1.03
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res (2009) 1.02
Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J Cell Biol (2009) 1.01
E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer (2014) 1.01
Endometrial-peritoneal interactions during endometriotic lesion establishment. Am J Pathol (2008) 1.01
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther (2012) 1.01